BioTelemetry (BEAT) Receives Daily News Sentiment Score of 0.16
Media coverage about BioTelemetry (NASDAQ:BEAT) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 46.187460682006 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s analysis:
- BioTelemetry, Inc. (BEAT) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Stocks Under Scanner in the Medical Research Space — Organovo, BioTelemetry, Bruker, and PerkinElmer (bizjournals.com)
- Analysts focus on Buy position: BioTelemetry, Inc. (BEAT) – Street Observer (press release) (streetobserver.com)
- Volatile Movements: Natus Medical Incorporated, (NASDAQ:BABY), BioTelemetry, Inc., (NASDAQ:BEAT) – Stocks In The News (press release) (tradingnewsnow.com)
- How Did BioTelemetry Inc’s (BEAT) 39.58% ROE Fare Against The Industry? (finance.yahoo.com)
A number of research firms have recently commented on BEAT. Benchmark Co. began coverage on BioTelemetry in a report on Thursday, June 29th. They issued a “buy” rating and a $38.00 price objective on the stock. Lake Street Capital restated a “buy” rating and issued a $50.00 price objective (up from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. BidaskClub downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Dougherty & Co raised their price objective on BioTelemetry from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Sidoti restated a “buy” rating and issued a $49.00 price objective (up from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. BioTelemetry presently has an average rating of “Buy” and an average target price of $44.40.
BioTelemetry (NASDAQ:BEAT) traded down 1.07% during trading on Wednesday, hitting $32.25. The stock had a trading volume of 260,034 shares. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 21.64 and a beta of 0.68. BioTelemetry has a 1-year low of $15.25 and a 1-year high of $39.20. The firm’s 50 day moving average is $34.70 and its 200 day moving average is $32.17.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The company had revenue of $58.10 million during the quarter, compared to analysts’ expectations of $58.39 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, analysts anticipate that BioTelemetry will post $0.99 earnings per share for the current year.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.